Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems

Background: Schistosomiasis is a water-borne disease afflicting over 261 million people in many areas of the developing countries with high morbidity and mortality. The control relies mainly on treatment with praziquantel. Fatty acid binding proteins (FABP) have demonstrated high levels of immune-pr...

Full description

Autores:
Vicente B.
López-Abán J.
Rojas Caraballo, Jose Vicente
Del Olmo E.
Fernández-Soto P.
Muro A.
Tipo de recurso:
Article of journal
Fecha de publicación:
2016
Institución:
Universidad Cooperativa de Colombia
Repositorio:
Repositorio UCC
Idioma:
OAI Identifier:
oai:repository.ucc.edu.co:20.500.12494/41841
Acceso en línea:
https://doi.org/10.16925/sp.v9i18.548
https://revistas.unab.edu.co/index.php/medunab/article/view/2272/2806
https://hdl.handle.net/20.500.12494/41841
Palabra clave:
fatty acid binding protein
gamma interferon
immunoglobulin E antibody
immunoglobulin G antibody
immunoglobulin G1 antibody
immunoglobulin G2a antibody
immunoglobulin M antibody
immunomodulating agent
interleukin 2
interleukin 4
interleukin 6
Schistosoma vaccine
tumor necrosis factor alpha
fatty acid binding protein
helminth antibody
helminth protein
interleukin 2
interleukin 4
recombinant protein
animal experiment
animal model
animal tissue
antibody response
Article
Baculoviridae
cercaria
controlled study
cytokine production
Escherichia coli
Fasciola hepatica
female
intestine
mouse
nonhuman
parasite load
schistosomiasis mansoni
spleen cell
animal
Bagg albino mouse
cross protection
drug delivery system
Fasciola hepatica
genetics
human
immunology
parasitology
schistosomiasis mansoni
vaccination
Animals
Antibodies
Helminth
Cross Protection
Drug Delivery Systems
Fasciola hepatica
Fatty Acid-Binding Proteins
Female
Helminth Proteins
H
Rights
closedAccess
License
http://purl.org/coar/access_right/c_14cb
id COOPER2_8c530ebff29c0939a09a83a02e9e2c76
oai_identifier_str oai:repository.ucc.edu.co:20.500.12494/41841
network_acronym_str COOPER2
network_name_str Repositorio UCC
repository_id_str
dc.title.spa.fl_str_mv Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems
title Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems
spellingShingle Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems
fatty acid binding protein
gamma interferon
immunoglobulin E antibody
immunoglobulin G antibody
immunoglobulin G1 antibody
immunoglobulin G2a antibody
immunoglobulin M antibody
immunomodulating agent
interleukin 2
interleukin 4
interleukin 6
Schistosoma vaccine
tumor necrosis factor alpha
fatty acid binding protein
helminth antibody
helminth protein
interleukin 2
interleukin 4
recombinant protein
animal experiment
animal model
animal tissue
antibody response
Article
Baculoviridae
cercaria
controlled study
cytokine production
Escherichia coli
Fasciola hepatica
female
intestine
mouse
nonhuman
parasite load
schistosomiasis mansoni
spleen cell
animal
Bagg albino mouse
cross protection
drug delivery system
Fasciola hepatica
genetics
human
immunology
parasitology
schistosomiasis mansoni
vaccination
Animals
Antibodies
Helminth
Cross Protection
Drug Delivery Systems
Fasciola hepatica
Fatty Acid-Binding Proteins
Female
Helminth Proteins
H
title_short Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems
title_full Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems
title_fullStr Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems
title_full_unstemmed Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems
title_sort Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems
dc.creator.fl_str_mv Vicente B.
López-Abán J.
Rojas Caraballo, Jose Vicente
Del Olmo E.
Fernández-Soto P.
Muro A.
dc.contributor.author.none.fl_str_mv Vicente B.
López-Abán J.
Rojas Caraballo, Jose Vicente
Del Olmo E.
Fernández-Soto P.
Muro A.
dc.subject.spa.fl_str_mv fatty acid binding protein
gamma interferon
immunoglobulin E antibody
immunoglobulin G antibody
immunoglobulin G1 antibody
immunoglobulin G2a antibody
immunoglobulin M antibody
immunomodulating agent
interleukin 2
interleukin 4
interleukin 6
Schistosoma vaccine
tumor necrosis factor alpha
fatty acid binding protein
helminth antibody
helminth protein
interleukin 2
interleukin 4
recombinant protein
animal experiment
animal model
animal tissue
antibody response
Article
Baculoviridae
cercaria
controlled study
cytokine production
Escherichia coli
Fasciola hepatica
female
intestine
mouse
nonhuman
parasite load
schistosomiasis mansoni
spleen cell
animal
Bagg albino mouse
cross protection
drug delivery system
Fasciola hepatica
genetics
human
immunology
parasitology
schistosomiasis mansoni
vaccination
Animals
Antibodies
Helminth
Cross Protection
Drug Delivery Systems
Fasciola hepatica
Fatty Acid-Binding Proteins
Female
Helminth Proteins
H
topic fatty acid binding protein
gamma interferon
immunoglobulin E antibody
immunoglobulin G antibody
immunoglobulin G1 antibody
immunoglobulin G2a antibody
immunoglobulin M antibody
immunomodulating agent
interleukin 2
interleukin 4
interleukin 6
Schistosoma vaccine
tumor necrosis factor alpha
fatty acid binding protein
helminth antibody
helminth protein
interleukin 2
interleukin 4
recombinant protein
animal experiment
animal model
animal tissue
antibody response
Article
Baculoviridae
cercaria
controlled study
cytokine production
Escherichia coli
Fasciola hepatica
female
intestine
mouse
nonhuman
parasite load
schistosomiasis mansoni
spleen cell
animal
Bagg albino mouse
cross protection
drug delivery system
Fasciola hepatica
genetics
human
immunology
parasitology
schistosomiasis mansoni
vaccination
Animals
Antibodies
Helminth
Cross Protection
Drug Delivery Systems
Fasciola hepatica
Fatty Acid-Binding Proteins
Female
Helminth Proteins
H
description Background: Schistosomiasis is a water-borne disease afflicting over 261 million people in many areas of the developing countries with high morbidity and mortality. The control relies mainly on treatment with praziquantel. Fatty acid binding proteins (FABP) have demonstrated high levels of immune-protection against trematode infections. This study reports the immunoprotection induced by cross-reacting Fasciola hepatica FABP, native (nFh12) and recombinantly expressed using two different expression systems Escherichia coli (rFh15) and baculovirus (rFh15b) against Schistosoma mansoni infection. Methods: BALB/c mice were vaccinated with native nFh12 or recombinant rFh15 and rFh15 FABP from F. hepatica formulated in adjuvant adaptation (ADAD) system with natural or chemical synthesised immunomodulators (PAL and AA0029) and then challenged with 150 cercariae of S. mansoni. Parasite burden, hepatic lesions and antibody response were studied in vaccination trials. Furthermore differences between rFh15 and rFh15b immunological responses (cytokine production, splenocyte population and antibody levels) were studied. Results: Vaccination with nFh12 induced significant reductions in worm burden (83 %), eggs in tissues (82-92 %) and hepatic lesions (85 %) compared to infected controls using PAL. Vaccination with rFh15 showed lower total worm burden (56-64 %), eggs in the liver (21-61 %), eggs in the gut (30-77 %) and hepatic damage (67-69 %) using PAL and AA0029 as immunomodulators. In contrast, mice vaccinated with rFh15b showed only reductions in eggs trapped in the liver and intestine (53 and 60 %, respectively), and hepatic lesions (45 %). We observed a significant rise in TNFa, IL-6, IL-2, IL-4 and high antibody response (IgG, IgG1, IgG2a, IgM and IgE) in mice immunised with either rFh15 or rFh15b. Moreover, mice immunised with rFh15b showed an increase in IFN? and a decrease in B220 cells compared to untreated mice, and less production of IgG1 and IgM than in mice immunised by rFh15. Conclusions: Higher level of protection is obtained by using Fasciola hepatica-derived FABP protein against Schistosoma mansoni infection. Native FABP is more effective than both recombinant systems. It could be due to post-translational modifications or FABP isoform or changes in the recombinant proteins. © 2016 Vicente et al.
publishDate 2016
dc.date.issued.none.fl_str_mv 2016
dc.date.accessioned.none.fl_str_mv 2021-12-16T22:15:50Z
dc.date.available.none.fl_str_mv 2021-12-16T22:15:50Z
dc.type.none.fl_str_mv Artículo
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coar.none.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.coarversion.none.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/article
dc.type.redcol.none.fl_str_mv http://purl.org/redcol/resource_type/ART
dc.type.version.none.fl_str_mv info:eu-repo/semantics/publishedVersion
format http://purl.org/coar/resource_type/c_6501
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.16925/sp.v9i18.548
https://revistas.unab.edu.co/index.php/medunab/article/view/2272/2806
dc.identifier.issn.spa.fl_str_mv 17563305
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.12494/41841
dc.identifier.bibliographicCitation.spa.fl_str_mv Vicente B,López J,Rojas J,Del Olmo E,Fernández P,Muro A. Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems. Parasit Vectors. 2016. 9. (1):p. 216-216. .
url https://doi.org/10.16925/sp.v9i18.548
https://revistas.unab.edu.co/index.php/medunab/article/view/2272/2806
https://hdl.handle.net/20.500.12494/41841
identifier_str_mv 17563305
Vicente B,López J,Rojas J,Del Olmo E,Fernández P,Muro A. Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems. Parasit Vectors. 2016. 9. (1):p. 216-216. .
dc.relation.ispartofjournal.spa.fl_str_mv PARASITE VECTOR
dc.rights.accessrights.none.fl_str_mv info:eu-repo/semantics/closedAccess
dc.rights.coar.none.fl_str_mv http://purl.org/coar/access_right/c_14cb
eu_rights_str_mv closedAccess
rights_invalid_str_mv http://purl.org/coar/access_right/c_14cb
dc.format.extent.spa.fl_str_mv 216-216
dc.publisher.spa.fl_str_mv BioMed Central Ltd.
institution Universidad Cooperativa de Colombia
repository.name.fl_str_mv Repositorio Institucional Universidad Cooperativa de Colombia
repository.mail.fl_str_mv bdigital@metabiblioteca.com
_version_ 1814246930517065728
spelling Vicente B.López-Abán J.Rojas Caraballo, Jose VicenteDel Olmo E.Fernández-Soto P.Muro A.2021-12-16T22:15:50Z2021-12-16T22:15:50Z2016https://doi.org/10.16925/sp.v9i18.548https://revistas.unab.edu.co/index.php/medunab/article/view/2272/280617563305https://hdl.handle.net/20.500.12494/41841Vicente B,López J,Rojas J,Del Olmo E,Fernández P,Muro A. Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems. Parasit Vectors. 2016. 9. (1):p. 216-216. .Background: Schistosomiasis is a water-borne disease afflicting over 261 million people in many areas of the developing countries with high morbidity and mortality. The control relies mainly on treatment with praziquantel. Fatty acid binding proteins (FABP) have demonstrated high levels of immune-protection against trematode infections. This study reports the immunoprotection induced by cross-reacting Fasciola hepatica FABP, native (nFh12) and recombinantly expressed using two different expression systems Escherichia coli (rFh15) and baculovirus (rFh15b) against Schistosoma mansoni infection. Methods: BALB/c mice were vaccinated with native nFh12 or recombinant rFh15 and rFh15 FABP from F. hepatica formulated in adjuvant adaptation (ADAD) system with natural or chemical synthesised immunomodulators (PAL and AA0029) and then challenged with 150 cercariae of S. mansoni. Parasite burden, hepatic lesions and antibody response were studied in vaccination trials. Furthermore differences between rFh15 and rFh15b immunological responses (cytokine production, splenocyte population and antibody levels) were studied. Results: Vaccination with nFh12 induced significant reductions in worm burden (83 %), eggs in tissues (82-92 %) and hepatic lesions (85 %) compared to infected controls using PAL. Vaccination with rFh15 showed lower total worm burden (56-64 %), eggs in the liver (21-61 %), eggs in the gut (30-77 %) and hepatic damage (67-69 %) using PAL and AA0029 as immunomodulators. In contrast, mice vaccinated with rFh15b showed only reductions in eggs trapped in the liver and intestine (53 and 60 %, respectively), and hepatic lesions (45 %). We observed a significant rise in TNFa, IL-6, IL-2, IL-4 and high antibody response (IgG, IgG1, IgG2a, IgM and IgE) in mice immunised with either rFh15 or rFh15b. Moreover, mice immunised with rFh15b showed an increase in IFN? and a decrease in B220 cells compared to untreated mice, and less production of IgG1 and IgM than in mice immunised by rFh15. Conclusions: Higher level of protection is obtained by using Fasciola hepatica-derived FABP protein against Schistosoma mansoni infection. Native FABP is more effective than both recombinant systems. It could be due to post-translational modifications or FABP isoform or changes in the recombinant proteins. © 2016 Vicente et al.josev.rojas@campusucc.edu.co216-216BioMed Central Ltd.fatty acid binding proteingamma interferonimmunoglobulin E antibodyimmunoglobulin G antibodyimmunoglobulin G1 antibodyimmunoglobulin G2a antibodyimmunoglobulin M antibodyimmunomodulating agentinterleukin 2interleukin 4interleukin 6Schistosoma vaccinetumor necrosis factor alphafatty acid binding proteinhelminth antibodyhelminth proteininterleukin 2interleukin 4recombinant proteinanimal experimentanimal modelanimal tissueantibody responseArticleBaculoviridaecercariacontrolled studycytokine productionEscherichia coliFasciola hepaticafemaleintestinemousenonhumanparasite loadschistosomiasis mansonispleen cellanimalBagg albino mousecross protectiondrug delivery systemFasciola hepaticageneticshumanimmunologyparasitologyschistosomiasis mansonivaccinationAnimalsAntibodiesHelminthCross ProtectionDrug Delivery SystemsFasciola hepaticaFatty Acid-Binding ProteinsFemaleHelminth ProteinsHProtection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systemsArtículohttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1http://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionPARASITE VECTORinfo:eu-repo/semantics/closedAccesshttp://purl.org/coar/access_right/c_14cbPublication20.500.12494/41841oai:repository.ucc.edu.co:20.500.12494/418412024-08-20 16:19:08.877metadata.onlyhttps://repository.ucc.edu.coRepositorio Institucional Universidad Cooperativa de Colombiabdigital@metabiblioteca.com